Labyrinthin-based peptides for cancer immunotherapies and uses thereof
AssigneeLabyRx Immunologic Therapeutics (USA) Limited
InventorsJames A. Radosevich, Michael Babich
Life of this patent
Estimating the term…
Abstract
Antigenic compositions comprising one or more labyrinthin-derived peptides are described herein. In some embodiment, each peptide of the antigenic composition comprises a T-cell epitope and/or a B-cell epitope. In other aspects, the present disclosure provides, e.g., vaccine compositions comprising tin antigenic composition disclosed herein, including kits, medicines, and compositions (such as pharmaceutical compositions and unit dosages) thereof. Also provided are methods of using the compositions disclosed herein, such as methods of treatment thereof and methods of producing antibodies, and antibody compositions thereof, against the one or more labyrinthin-derived peptides or a portion thereof.
Claims1
A method for treating a labyrinthin-positive adenocarcinoma in an individual in need thereof, the method comprising administering to the individual having the labyrinthin-positive adenocarcinoma a vaccine composition comprising:
- (a) an effective amount of an antigenic composition comprising:
- (i) a first peptide consisting of SEQ ID NO:29;
- (ii) a second peptide consisting of SEQ ID NO:30;
- (iii) a third peptide consisting of SEQ ID NO:31;
- and
- (iv) a fourth peptide consisting of SEQ ID NO:32;
- and
- (b) a pharmaceutically acceptable vehicle.
Dependencies are inferred from the claim text.